BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26153638)

  • 1. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
    Albiges L; Escudier B
    Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
    Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
    Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
    Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-Line Treatment Options for Kidney Cancer.
    Posadas EM; Limvorasak S; Figlin RA
    Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
    [No Abstract]   [Full Text] [Related]  

  • 6. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
    Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
    J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies.
    Suárez C; Díaz-Mejía N; Morales-Barrera R; González M; Mateo J; Carles J
    Curr Opin Urol; 2021 May; 31(3):242-248. PubMed ID: 33742977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncotargets in different renal cancer subtypes.
    Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
    Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
    Saleeb RM; Farag M; Lichner Z; Brimo F; Bartlett J; Bjarnason G; Finelli A; Rontondo F; Downes MR; Yousef GM
    Mol Oncol; 2018 Oct; 12(10):1673-1688. PubMed ID: 29896907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving therapeutic targets in renal cell carcinoma.
    Singer EA; Gupta GN; Marchalik D; Srinivasan R
    Curr Opin Oncol; 2013 May; 25(3):273-80. PubMed ID: 23455028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal cell carcinoma].
    Tomita Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
    Gross-Goupil M; Massard C; Ravaud A
    Curr Urol Rep; 2012 Feb; 13(1):16-23. PubMed ID: 22139625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.